Meinhardt Group will help in the design of the master plan for the first stage of the “New Tashkent”

According to gazeta.uz, Uzbekistan plans to attract the Meinhardt Group, an engineering and investment company from Singapore, to design the master plan for the first stage of construction of the New Tashkent smart city worth $1 billion. It can also take part in projects for the production of alkylbenzene and caustic soda.

Uzbekistan and Singapore will create a Design and Engineering Center to develop and implement the “New Tashkent” smart city project, the press service of the Ministry of Investment, Industry and Trade (MIIT) reported.

The corresponding agreement was signed at a meeting between the head of the MIIT, Laziz Kudratov, and the head of the Meinhardt Group, Shahzad Naseem, during the meeting on January 14.

In particular, the main task of the center will be the implementation of urban planning and industrial initiatives. We are talking about the design of the master plan for the first stage of the construction of the “Yangi Toshkent” (“New Tashkent”) smart city and a number of industrial enterprises for the production of chemical and pharmaceutical products. Training of personnel for the center will be carried out by the Singapore side.

According to the agreement, the center is planned to be launched in February-March, and the concept of the master plan for the “New Tashkent” project is to be developed in April-May. Development of a detailed project plan is expected in July-October. The cost of the agreement is estimated at $1 billion.

In addition, Meinhardt Group, together with “Uzkimyosnoat”, plans to launch the production of alkylbenzene for detergents in the Kashkadarya region. The project is estimated at $231 million. Completion of the development of a feasibility study for the project is scheduled for April-May, and the start of work to attract investors is scheduled for July-August.

In addition, the company is also considering the implementation of a project for the production of caustic soda in the Khorezm region for $220 million.

It is also expected to create a pharmaceutical enterprise in the Tashkent region for the production of immunobiological drugs for $49 million.